Key statistics
On Friday, Alnylam Pharmaceuticals Inc (DUL:FRA) closed at 242.80, -10.74% below its 52-week high of 272.00, set on Aug 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 242.80 |
---|---|
High | 242.80 |
Low | 242.80 |
Bid | 243.60 |
Offer | 244.60 |
Previous close | 244.10 |
Average volume | 414.20 |
---|---|
Shares outstanding | 128.38m |
Free float | 127.84m |
P/E (TTM) | -- |
Market cap | 34.40bn USD |
EPS (TTM) | -0.6285 USD |
Data delayed at least 15 minutes, as of Oct 04 2024 07:20 BST.
More ▼
Press releases
- Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024
- Alnylam to Webcast TTR Investor Day
- Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
- Alnylam to Webcast Presentations at Upcoming September Investor Conferences
- Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024
- Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity
- Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
More ▼